Objective: To assess whether pretreatment theta current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC) differentiates responders from non-responders to antidepressant medication or placebo in a double-blinded study. Methods: Pretreatment EEGs were collected from 72 subjects with Major Depressive Disorder (MDD) who participated in one of three placebo-controlled trials. Subjects were randomized to receive treatment with fluoxetine, venlafaxine, or placebo. Low-resolution brain electromagnetic tomography (LORE-TA) was used to assess theta current density in the rACC and mOFC. Results: Medication responders showed elevated rACC and mOFC theta current density compared to medication non-responders (rACC: p = 0.042; mOFC: p = 0.039). There was no significant difference in either brain region between placebo responders and placebo non-responders. Conclusions: Theta current density in the rACC and mOFC may be useful as a biomarker for prediction of response to antidepressant medication. Significance: This is the first double-blinded treatment study to examine pretreatment rACC and mOFC theta current density in relation to antidepressant response and placebo response. Results support the potential clinical utility of this approach for predicting clinical outcome to antidepressant treatments in MDD.
Introduction
Major Depressive Disorder (MDD) is difficult to treat, as fewer than 60% of patients respond to an initial 8-week trial of common antidepressant medications (Papakostas et al., 2007; Quitkin et al., 2000) . Treatment of MDD would be improved by biomarkers that predicted response to a particular treatment so that those at greatest risk of non-response could receive alternate treatments. EEG biomarkers would be particularly practical to help direct treatment of MDD due to the inexpensive and non-invasive nature of the method. One such potential biomarker of treatment response is theta current density in both the rostral anterior cingulate cortex (rACC) and medial orbitofrontal cortex (mOFC), a subregion of prefrontal cortex (PFC), as there is evidence to suggest that response is associated with pretreatment neurophysiologic activity in these areas (Mayberg et al., 1997; Mulert et al., 2007b; Pizzagalli et al., 2001; Saxena et al., 2003; Wu et al., 1999) .
Neuroimaging studies of brain metabolism in MDD have shown that responders to antidepressant medication have elevated pretreatment resting metabolism in the rACC and medial PFC compared to non-responders (Mayberg et al., 1997; Saxena et al., 2003) . This finding is not limited to pharmacotherapy interventions, as responders to sleep deprivation have also been shown to have elevated rACC and mOFC metabolism compared to nonresponders (Wu et al., 1999) , as well as elevated OFC perfusion (Volk et al., 1997) .
Brain function and treatment response in MDD also have been studied using quantitative electroencephalographic (QEEG) imaging with low-resolution electromagnetic tomography (LORETA) (Pascual-Marqui et al., 1999) . LORETA is a widely used EEG source localization tool that computes sources of brain electrical activity from a linear weighted sum of scalp electrical potentials. The LORETA solution space is constrained to cortical gray matter, as cortical pyramidal cells are assumed to be the source of the EEG signal (Gloor, 1985) . LORETA's ability to localize EEG sources has been validated against magnetic resonance imaging (MRI) (Worrell et al., 2000) , functional MRI (fMRI) (Seeck et al., 1998) 
